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Insulin Resistance and
Compensatory Hyperinsulinemia
The Key Player Between Cigarette Smoking and Cardiovascular Disease?
Gerald Reaven, MD, Philip S. Tsao, PHD
Stanford, California
Hyperinsulinemia, dyslipidemia, and endothelial dysfunction are characteristic findings in
insulin-resistant individuals, and all of these abnormalities have been identified as increasing
cardiovascular disease (CVD) risk. Smokers tend to be relatively insulin resistant, hyperin-
sulinemic, and dyslipidemic, with evidence of endothelial dysfunction, as compared with
nonsmokers, and recent epidemiologic data have suggested that CVD in smokers is primarily
seen in those individuals who also have the characteristic findings of insulin resistance. Based
on these observations, it is argued that insulin resistance and its consequences represent a
major mechanistic link between cigarette smoking and CVD. It is also postulated that the
enhanced CVD risk in smokers, resulting from hyperinsulinemia, abnormalities of lipoprotein
metabolism, and endothelial dysfunction, will primarily be present in those smokers who are
insulin resistant. As a corollary, it is suggested that CVD risk in individuals who cannot, or
will not, stop smoking can be reduced by therapeutic efforts aimed at attenuating the adverse
effects of insulin resistance and its consequences. (J Am Coll Cardiol 2003;41:1044–7)
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Smoking is a major risk factor for atherosclerosis and
cardiovascular disease (CVD), with a dose-response corre-
lation between CVD morbidity and mortality and the
number of cigarettes smoked (1). Although this relationship
is well recognized, the pathophysiologic links between
smoking and CVD have not been resolved. For example, the
results of studies to be reviewed subsequently have demon-
strated that smokers have abnormalities in lipoprotein
metabolism and endothelial function known to be associ-
ated with increased CVD risk. Although these changes in
lipid metabolism and endothelial function provide attractive
mechanistic links between smoking and CVD, neither one
need be an independent risk factor for CVD in smokers.
More specifically, there is evidence that smokers are insulin
resistant and hyperinsulinemic, as compared with nonsmok-
ers (2–9), and these changes can lead to both the dyslipi-
demia (10) and endothelial dysfunction (11) shown to be
present in smokers. Furthermore, recent data from the
Copenhagen male study indicated that only those smokers
who have the characteristic dyslipidemia associated with
insulin resistance/compensatory hyperinsulinemia were at
greatly increased CVD risk (12). Thus, it can be argued that
a major defect leading to increased CVD risk in smokers is
insulin resistance and compensatory hyperinsulinemia, and
that the multiple adverse consequences associated with these
changes in insulin metabolism, including dyslipidemia and
endothelial dysfunction, are responsible for the accelerated
atherogenesis in these individuals. If this formulation is
correct, the prevalence of these abnormalities will be in-
creased primarily in those smokers who are also insulin
resistant. The untoward effects of insulin resistance and
compensatory hyperinsulinemia provide a mechanistic link
between smoking and CVD that is consistent with available
data, as well as offering a new and clinically relevant
approach to decreasing CVD risk in those smokers who
cannot, or will not, stop smoking.
SMOKING AND INSULIN RESISTANCE
In 1992, we demonstrated that smokers were insulin resis-
tant and hyperinsulinemic, as compared with a matched
group of nonsmokers (2). The initial report that smokers
were relatively more insulin resistant than nonsmokers was
soon confirmed, and evidence was subsequently published
indicating that smoking 1 cigarette per h for 6 h was
associated with a decrease in insulin sensitivity (3). In
addition to these studies showing smoking to be associated
with direct measures of insulin resistance, other population-
based reports have indicated that smokers have higher
insulin levels (a surrogate marker of insulin resistance) than
nonsmokers (4–6). Furthermore, despite the observation
that smoking cessation was associated with weight gain, it
was possible to document an improvement in insulin sen-
sitivity at the same time (7). Finally, smoking has been
shown to accentuate the degree of insulin resistance in
patients with type 2 diabetes (8,9). However, in one
population-based study, smokers did not have higher
plasma insulin concentrations than did nonsmokers (13).
Also, in another study using the minimal model to quantify
insulin action, no difference in insulin sensitivity was noted
From Stanford University School of Medicine, Stanford, California.
Manuscript received September 5, 2002; revised manuscript received November 11,
2002, accepted November 27, 2002.
Journal of the American College of Cardiology Vol. 41, No. 6, 2003
© 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00
Published by Elsevier Science Inc. doi:10.1016/S0735-1097(02)02982-0
between smokers and nonsmokers (14), but this latter
finding is confounded by the fact that although active
smoking was not associated with insulin resistance, exposure
to environmental tobacco smoke was. Consequently, there is
considerable support for the view that smokers are insulin
resistant and hyperinsulinemic as compared with nonsmok-
ers. On the other hand, although smokers, as a group, are
more insulin resistant than nonsmokers, not all smokers are
insulin resistant (2). Perhaps the best way to view the
metabolic effect of smoking is as a modulating factor that
will adversely affect insulin-mediated glucose disposal, and
the more intrinsically insulin resistant an individual is, the
greater will be the untoward effect of smoking.
SMOKING, DYSLIPIDEMIA, AND INSULIN RESISTANCE
The fact that smokers have higher plasma triglyceride (TG)
and lower high-density lipoprotein (HDL) cholesterol con-
centrations than nonsmokers has been apparent for many
years (15–17). Indeed, it was the similarity between the
dyslipidemia described in smokers and that characteristic of
insulin resistance (10) that led to the initiation of our study
showing that smokers were insulin resistant as compared
with nonsmokers (2). In that study, we were also able to
demonstrate that insulin resistance, compensatory hyperin-
sulinemia, and high TG and low HDL cholesterol concen-
trations appeared together as a cluster in smokers. The
association between smoking, insulin resistance, and dyslip-
idemia has also been observed in subsequent studies show-
ing the powerful impact of the combined effects of smoking
and hyperinsulinemia on plasma TG and HDL cholesterol
concentrations in patients with combined hyperlipidemia
(18), and that the cluster of metabolic abnormalities asso-
ciated with insulin resistance and compensatory hyperinsu-
linemia was increased sixfold in smokers (19). Thus, there is
substantial evidence that the combination of insulin resis-
tance, hyperinsulinemia, and the dyslipidemia characteristic
of insulin resistance occurs together in smokers more
commonly than in nonsmokers. The clinical relevance of
this association has been emphasized by evidence showing
that the increased prevalence of CVD in smokers was
almost entirely confined to those individuals who also had
high TG and low HDL cholesterol concentrations (12).
SMOKING, ENDOTHELIAL
DYSFUNCTION, AND INSULIN RESISTANCE
Several lines of evidence have shown that endothelial
function is abnormal when smokers are compared with
nonsmokers. For example, endothelial-dependent blood
flow following venous occlusion is decreased in smokers
(20–24), as was the vasodilatory response to bradykinin in
the perfused hand vein (25) and the vasomotor response of
epicardial coronary arteries to cold pressor testing (26). In
addition to these apparent changes in endothelial function,
mononuclear cells from smokers bind with greater adher-
ence to cultured endothelium (27), and plasma concentra-
tions of cellular adhesions molecules are increased in these
individuals, in association with higher plasma insulin con-
centrations (28).
The possibility that insulin resistance and/or compensa-
tory hyperinsulinemia mediates the association between
smoking and endothelial dysfunction is consistent with
several lines of evidence. There are significant relationships
between insulin resistance and/or compensatory hyperinsu-
linemia and markers of endothelial dysfunction, including
enhanced binding of mononuclear cells isolated from pe-
ripheral blood to cultured endothelium (29), increased
plasma concentrations of several cellular adhesion molecules
(30), partially oxidized low-density lipoprotein (LDL) par-
ticles (31), and decreased plasma concentrations of antiox-
idant vitamins (32). More recently, we have demonstrated a
highly significant relationship between the degree of insulin
resistance and plasma concentrations of asymmetric dim-
ethylarginine (ADMA) (33). Asymmetric dimethylarginine
is an endogenous inhibitor of nitric oxide synthase, recently
shown to predict CVD in patients with renal failure (34), as
well as acute coronary events in a population-based study in
Finland (35). The potential importance of elevated ADMA
levels as a CVD risk factor has recently been emphasized in
a Lancet editorial (36). Finally, endothelial dysfunction is
associated with reduced arterial compliance, and increased
arterial stiffness has been described in smokers, as well as in
two clinical conditions characterized by insulin resistance
type 2 diabetes and hypertension (37).
CLINICAL IMPLICATIONS
The most effective way for smokers to decrease the risk of
CVD is to stop smoking. However, not all smokers are
either willing or able to make this behavioral change. The
information outlined in this Viewpoint provides the exper-
imental background that can help decrease the CVD risk in
those individuals who cannot stop smoking. At the simplest
level, it is essential that health care professionals realize that
insulin resistance and its consequences are accentuated in
smokers, that these abnormalities increase the CVD risk,
and that smokers should be evaluated for evidence of insulin
resistance and its consequences. Perhaps the simplest was to
do this is to use the recent criteria suggested by the Adult
Abbreviations and Acronyms
ADMA  asymmetric dimethylarginine
ATP-III  Adult Treatment Panel III
CVD  cardiovascular disease
HDL  high-density lipoprotein
LDL  low-density lipoprotein
TG  triglycerides
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Treatment Panel III (ATP-III) for identifying individuals
with the metabolic syndrome (38). Although somewhat
arbitrary, the ATP-III criteria provide a useful approach to
decide which smokers also appear to be insulin resistant and
in whom efforts should be initiated aimed at improving
insulin sensitivity, as well as addressing the adverse mani-
festations of insulin resistance.
A complete discussion of the therapeutic interventions to
decreasing the CVD risk in insulin-resistant smokers is
outside the scope of this Viewpoint, but a few general
comments appear to be appropriate. To begin with, it is
necessary to differentiate between efforts focused on improv-
ing insulin sensitivity, per se, and those aimed at treating the
specific manifestations of insulin resistance/compensatory
hyperinsulinemia. Both adiposity and the level of physical
activity are powerful modulators of insulin-mediated glu-
cose disposal (39) and, in contrast to the other factors that
affect insulin action, they are modifiable by safe, straight-
forward lifestyle changes. Thus, weight loss of 5% to 10% of
body weight in overweight or obese individuals who are also
insulin resistant significantly enhances insulin sensitivity,
lowers ambient plasma insulin concentrations, and improves
the associated CVD risk factors (40). An increase in
physical activity in insulin-resistant individuals is also of
considerable utility and provides two benefits. At the sim-
plest level, any increase in energy expenditure will help
insulin-resistant individuals maintain or lose weight. The
greater the magnitude of the increase in energy expenditure,
the greater will be the benefit to the individual. It is also
possible to directly enhance insulin sensitivity if an individ-
ual is able to exercise for approximately 30 to 40 min, 4
times/week. The beneficial effects of the combination of
modest weight loss and increased physical activity were
clearly demonstrated in studies showing that these lifestyle
changes decreased the rate at which type 2 diabetes devel-
oped in patients with impaired glucose tolerance (41,42).
Although macronutrient composition of the diet, by
itself, has little or no direct effect on insulin-mediated
glucose disposal, it modulates the dyslipidemic changes seen
in insulin-resistant smokers. Of greatest importance in this
context is the avoidance of low-fat/high-carbohydrate diets,
unless weight loss is also occurring. The more insulin
resistant an individual is, the more insulin he or she must
secrete to maintain normal glucose homeostasis. In the
absence of weight loss, the untoward manifestations of
insulin resistance/hyperinsulinemia will be accentuated
when insulin-resistant persons increase the amount of car-
bohydrate in their diet (43). A simple alternative, and one
consistent with efforts to minimize the intake of saturated
fat, is to replace saturated fat with unsaturated fat, rather
than with carbohydrate, thus maintaining a moderate car-
bohydrate intake. Parenthetically, this dietary manipulation
is as effective as low-fat/high-carbohydrate diets in lowering
LDL cholesterol concentrations (44,45).
Given the difficulty in changing one’s lifestyle, it could be
argued that the ideal treatment of insulin-resistant cigarette
smokers would be drug(s) that could significantly enhance
insulin sensitivity, as well as its related adverse conse-
quences. In this context, the use of thiazolidendione com-
pounds is of particular interest in that they are capable of
improving insulin sensitivity (46). However, thiazolidendi-
one compounds are currently approved by the Food and
Drug Administration only for the treatment of hyperglyce-
mia in patients with type 2 diabetes, and at the present time,
there are no compelling experimental data to establish their
clinical utility in other clinical situations
Finally, it seems reasonable to consider pharmacologic
treatment of the characteristic dyslipidemia of insulin-
resistant smokers (high TG and low HDL cholesterol
concentrations), an approach that has been useful in de-
creasing the CVD risk in a secondary CVD prevention trial
(47). Although a high LDL cholesterol concentration is not
associated with insulin resistance/hyperinsulinemia, evi-
dence from the Heart Protection Study (48) that simvastatin
administration decreased the CVD risk, irrespective of
smoking status, makes it seem reasonable to aggressively
treat hypercholesterolemia in smokers to the same degree as
is recommended for patients with type 2 diabetes (49).
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